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Microglial neuroinflammatory processes play a primary role in dopaminergic neurodegeneration for Parkinson’s disease 
(PD). This can occur, in part, by modulation of glial function following activation by soluble or insoluble modified alpha-
synuclein (α-syn), a chief component of Lewy bodies that is released from affected dopaminergic neurons. α-Syn is ni-
trated during oxidative stress responses and in its aggregated form, induces inflammatory microglial functions. Elu-
cidation of these microglial function changes in PD could lead to new insights into disease mechanisms. To this end, 
PD-associated inflammation was modeled by stimulation of microglia with aggregated and nitrated α-syn. These acti-
vated microglia were ameboid in morphology and elicited dopaminergic neurotoxicity. A profile of nitrated, aggregated 
α-syn-stimulated microglia was generated using combinations of genomic (microarrays) and proteomic (liquid chroma-
tography-tandem mass spectrometry, differential gel electrophoresis, and protein array) assays. Genomic studies re-
vealed a substantive role for nuclear factor-kappa B transcriptional activation. Qualitative changes in the microglial 
proteome showed robust increases in inflammatory, redox, enzyme, and cytoskeletal proteins supporting the genomic 
tests. Autopsy brain tissue acquired from substantia nigra and basal ganglia of PD patients demonstrated that parallel 
nuclear factor-kappa B-related inflammatory processes were, in part, active during human disease. Taken together, the 
transcriptome and proteome of nitrated α-syn activated microglia, shown herein, provide new potential insights into dis-
ease mechanisms.
Keywords: alpha-synuclein, microglia, neuroinflammation, Parkinson’s disease, proteomics
Abbreviations used: ACN, acetonitrile; AD, Alzheimer’s disease; AFM, atomic force microscopy; BG, basal ganglia; 
DIGE, differential gel electrophoresis; DMEM, Dulbecco’s modified Eagle’s medium; ex/em, excitation/emission; FBS, fe-
tal bovine serum; Gapdh, glyceraldehyde-3-phosphate dehydrogenase; IP, Immunoprecipitates; LB, Lewy bodies; LC-
MS/MS, liquid chromatography-tandem mass spectrometry; LPS, lipopolysaccharide; NF-κB, nuclear factor-kappa B; N-
α-syn, nitrated alpha synuclein; PBS, phosphate-buffered saline; PD, Parkinson’s disease; PVDF, polyvinylidene fluoride; 
RIPA, radioimmunoprecipitation; ROS, reactive oxygen species; SN, substantia nigra; SNpc, substantia nigra pars com-
pacta; TH, tyrosine hydroxylase; α-syn, alpha-synuclein.
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Parkinson’s disease (PD) is a progressive neurodegen-
erative disorder  characterized by  resting  tremor,  rigid-
ity, bradykinesia, and gait disturbances (Fahn et al. 1998; 
Mayeux 2003; Fahn and Sulzer 2004). Presently, 1.5 mil-
lion Americans are afflicted. Disease incidence rises with 
increasing age, with 120/100 000 contracting PD over the 
age of 70 (Dauer and Przedborski 2003). Pathologically, 
PD  is characterized by  the progressive  loss of dopami-
nergic neuronal cell bodies in the substantia nigra pars 
compacta (SNpc) and their termini in the dorsal striatum 
(Hornykiewicz and Kish 1987). These pathological find-
ings  commonly  parallel microglial  activation  observed 
in association with deposits of  aggregated alpha  synu-
clein (α-syn) in intracellular inclusions, known as Lewy 
bodies  (LB)  (Spillantini  et al.  1997; Croisier  et al.  2005). 
Although host genetics and environmental factors affect 
the onset and progression of PD (Tanner 1992) significant 
clinical, epidemiologic, and experimental data also sup-






understood.  One  line  of  investigation  is  that  neuronal 
death  itself drives microglial  immune  responses  (Gias-
son et al. 2000; Przedborski et al. 2001; Mandel et al. 2005). 
Alternatively, we, as well as others, have proposed that 
activation occurs as a  consequence of  release of  aggre-
gated proteins from the cytosol or within LB to the ex-
tracellular space. In this way, the death of dopaminergic 
neurons leads to release of modified protein aggregates 
that activate microglia  inciting a  lethal  cascade of neu-





sion of α-syn and PD pathogenesis are linked. This is de-
rived  from  the  discovery  that  mutations  and multiple 
copies of the gene encoding α-syn (SNCA  and PARK1) 
are linked to familial early onset PD (Kruger et al. 1998; 
Spira et al. 2001; Zarranz et al. 2004; (Singleton et al. 2003; 
Chartier-Harlin et al. 2004). Second, oxidation and nitra-
tion of α-syn leads to formation of aggregates and fila-
ments that comprise LB (Giasson et al. 2000; Souza et al. 
2000). Third, portions of α-syn are secreted rendering it 
more vulnerable to aggregation (Lee et al. 2005) and oxi-
dative modification (Kakimura et al. 2001). Fourth, α-syn 
itself  can  activate  microglia,  inducing  reactive  oxygen 
species (ROS) (Thomas et al. 2007) and subsequent neu-





Hong  2005).  Sixth,  endogenous  activators  of  microglia 
show a neuroinflammatory fingerprint reflective of what 









gregated α-syn (N-α-syn). N-α-syn stimulation of mi-
croglia  induced morphological  cell  transformation  and 
neurotoxic secretions. A N-α-syn-activated ‘microglial 
signature’ was determined by gene microarrays, 2D dif-
ferential in-gel electrophoresis (DIGE), and by cytokine 
profiling. N-α-syn induced a microglia inflammatory 
phenotype characterized by the expression of neurotoxic 
and neuroregulatory  factors. Most  importantly,  the  in-
flammatory signature seen in laboratory assays were, in 
part, mirrored  in parallel  tests  performed on postmor-
tem brain tissues from PD patients. These observations, 
taken together, serve to support both a ‘putative’ role for 




Parkinson’s disease brain tissues
Autopsy  materials  from  the  substantia  nigra  (SN)  and 





of  diseases  unrelated  to  neurological  impairments.  This  in-
cluded atherosclerotic and metabolic diseases, infections, and 
cancer (Table 1).
An antibody to N-α/β-syn (clone nSyn12, mouse ascites; 
Upstate, Charlottesville, VA, USA) that recognizes nitrated hu-
man N-α-syn (14.5 kDa) and N-β-syn (17 kDa) was used for im-
munoprecipitation. Samples of SN from control, AD, and PD 
autopsy brain tissues (Table 1) were homogenized in ice-cold 










phate-buffered saline (PBS), and resuspended in 20 μL of 1× 
electrophoresis sample buffer.
Nitrated-α-Syn IP (20 μL) were fractionated by 16% Tri-
cine  sodium  dodecyl  sulfate–polyacrylamide  gel  electropho-
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resis  (PAGE)  (Jule  Inc., Milford, CT, USA and BIORAD Lab-
oratories  Inc., Los Angeles, CA, USA) at constant voltage  for 
1.5 h. The gels were fixed and stained with Coomasie Blue to 
visualize protein bands. Bands corresponding  to  the molecu-
lar weights encompassing 14.5 kDa (α-syn) were excised, di-
gested by trypsin, column purified, and sequenced by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) for 
protein validation. Sequenced peptides were distinguished by 
peptide matches to the human α-syn sequence (NCBI Acces-
sion: AAI08276).
  
Purification, nitration, and aggregation of re-
combinant mouse α-syn
Purification, nitration, and aggregation of recombinant 
mouse α-syn were performed as previously described (Thomas 
et al. 2007). Five individual lots of α-syn were tested for en-
dotoxin by Limulus amebocyte lysate tests and all were below 




by  PAGE  using  4–12% NuPAGE  gels  (Invitrogen,  Carlsbad, 
CA, USA). After electrophoresis, the gels were transferred onto 
polyvinylidene fluoride (PVDF) membranes (Millipore, Biller-
ica, MA, USA) and probed with primary mouse IgG1 anti-α-
syn (1 : 500; Transduction Laboratories/BD Biosciences, Frank-
lin  Lakes, NJ, USA)  or  primary  rabbit  IgG  anti-nitrotyrosine 
(1 : 2000; Upstate). Signal was detected with horseradish per-
oxidase-conjugated  anti-mouse  IgG  or  anti-rabbit  IgG  (both 










Isolation, cultivation, and N-α-syn activation of 
murine microglia
Microglia  from C57BL/6 mice  neonates  (1-  to-2-days  old) 
were prepared according to well described techniques (Dobre-
nis 1998). All animal procedures were in accordance with Na-




cells were cultured for 7 days in Dulbecco’s Modified Eagle’s 
Medium  (DMEM)  containing  10%  fetal  bovine  serum  (FBS), 
10 μg/mL gentamicin, and 2 μg/mL macrophage colony stim-
ulating factor (a generous gift of Wyeth Inc., Cambridge, MA, 
USA). To obtain homogenous microglial cell populations, cul-
ture flasks were gently shaken and non-adherent microglia were 
transferred to new flasks. The flasks were incubated for 30 min 
to allow the microglia  to adhere, and  loose cells  removed by 
washing with DMEM. Microglia were plated at 2 × 106 cells per 
well in six-well plates in DMEM containing 10% FBS, 10 μg/
mL gentamicin, and 2 μg/mL macrophage colony stimulating 
factor. One week later, cells were stimulated with 100 nmol/L 





Inflammatory genomic and PCR assays
RNA from N-α-syn stimulated primary murine microglial 
cells and unstimulated control was extracted with TRIzol (In-
vitrogen), column purified (Qiagen, Valencia, CA, USA), pre-
cipitated with ammonium acetate, amplified and labeled using 
the T7-based TrueLabeling-AMP 2.0 kit (Superarray, Frederick, 
MD, USA).  The  resultant  cRNA was  hybridized  to  an  oligo-
Table 1.  Patient clinical profiles and neuropathological findingsa 
Patient Diagnosisb Gender Agec Durationd Neuropathologye
1 PD Female 78 25 Hypopigmentation and LB formation in SN and locus ceruleus
2 PSP Male 83 N/A Cerebral atrophy of frontal and superior temporal
3 PD Female 75 9 Idiopathic
4 PD Female 89 21 Idiopathic
5 PD Female 82 10 Neocortical LB
6 LBD Male 82 8 Neocortical LB and hippocampal sclerosis
7 PSP Male 82 24 Degeneration of subcortical nuclei with neurofibrillary tangles 
8 PD Male 67 17 Hypopigmentation, neuronal loss, gliosis, LB in SN, and locus ceruleus
9 PD Female 85 3 Hypopigmentation, gliosis, and neuronal loss in SN, globus    
      pallidus, and caudate-putamen
10 PD Male 86 5 Hypopigmentation, LB, neuronal loss in the SN and locus ceruleus
11 AD Male 73 8 Neuritic and diffuse plaques and neurofibrillary tangles in neocortex   
      and hippocampus. Neuronal loss in Locus ceruleus.
12 AD Female 84 N/A Remote infarct in the occipital lobe and cerebellum
13 AD Male 76 N/A Senile plaque-predominant AD
a Ten non-affected, age-matched controls were used for comparisons in this study; b Final diagnosis at autopsy; c Age at death; 
d Duration of disease (years) based on onset of initial symptoms and preliminary diagnosis; e Neuropathology at autopsy. 
PD, Parkinson’s disease; PSP, progressive subnuclear palsy; LBD, Lewy body disease; LB, Lewy bodies; SN, substantia nigra; 
N/A, data not available; AD, Alzheimer’s disease; N/A, data not available.
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based  microarray  for  mouse  general  pathway  (Superarray 
#OMM-014) and nuclear factor-kappa B (NF-κB)-related genes 
(Superarray #OMM-025). The arrays were washed, incubated 
sequentially  with  streptavidin-bound  alkaline  phosphatase 
and chemiluminescent substrate before exposure to X-ray film. 
Subsequent analysis of  the microarrays was performed using 
the GEArray expression analysis suite (Superarray).
Total  RNA  obtained  from  analysis  of  the microglial  tran-
scriptome  was  reverse  transcribed  with  random  hexam-
ers  and  SSII  reverse  transcriptase  (Applied  Biosystems,  Fos-
ter City, CA, USA). Murine-specific primer pairs were: Ccl2: 
CCCCAAGAAGGAATGGGTCC and GGTTGTGGAAAAGG-
TAGTGG; Il1β:  GTTCCTTTGTGGCACTTGGT  and  CTAT-
GCTGCCTGCTCTTACTGACT; Il10: CAGTTATTGTCTTCCC-
GGCTGTA  and  CTATGCTGCCTGCTCTTACTGACT;  Ifng: 
TTTGAGGTCAACAACAACCCACA  and  CGCAATCA-
CAGTCTTGGCTA;  and  Nos2:  5’-GGCAGCCTGTGAGA-
CCTTTG-3’  and  5’-GAAGCGTTTCGGGATCTGAA-3’.  Taq-
Man gene expression assays specific for murine Tnf, Tnfrsf1a, 
Stat1, Rela, Bdnf, and Gdnf were purchased from Applied Bio-
systems, and normalized to glyceraldehyde-3-phosphate dehy-
drogenase  (Gapdh)  expression. Tissue  samples obtained  from 
PD and control patients were snap frozen on dry ice and stored 
at −80°C. RNA was prepared from the samples using TRIzol 
reagent (Invitrogen) and purified with the RNeasy Mini Kit 
(Qiagen), prior to cDNA synthesis. Human specific primers 
for TNF, TNFRSF1A, STAT1, NFKB1, RELA, BDNF, and GDNF 









Microglia were plated at a density of 2 × 106 cells/well in a 
six-well plate and stimulated with 100 nmol/L aggregated N-
α-syn, and 100 ng/mL lipopolysaccharide (LPS, Escherichia coli; 
Sigma-Aldrich, St. Louis, MO, USA) in serum-free media. Fifty 
microliter aliquots were collected at 8, 24, and 72 h of incuba-
tion in triplicate and frozen at −80°C. For assay, the samples 
were analyzed using the BD Cytometric Bead Array Mouse In-
flammation Kit (BD Biosciences, San Jose, CA, USA) according 
to the manufacturer’s protocol. Samples of culture supernatants 
from microglia were diluted 1 : 3 and 1 : 10 in assay diluent and 







cultured  in  75-cm2 flasks in DMEM/F12 with 15 mmol/L 
HEPES  (Invitrogen)  containing  N2  supplement  (Invitrogen), 
100 U/mL of penicillin, 100 μg/mL streptomycin, and 5% FBS. 
Cells were grown to 80% confluence then co-cultured at 1 : 1 
ratio with previously plated microglial cells. To assess cell vi-
ability microglia cells were plated at a density of 5 × 104 cells 
on sterile glass coverslips, and co-cultures were prepared with 
a 1 : 1 ratio microglia: MES23.5 cells. After 24–48 h, cells were 
stimulated with aggregated 100 nmol/L N-α-syn or 100 nmol/
L α-syn for 4, 8, 24, and 72 h. CD11b+ microglial  cells  were 
distinguished  from MES23.5  cells by APC-conjugated CD11b 
(1 : 200;  Invitrogen)  immunocytochemistry.  For  tyrosine  hy-
droxylase (TH) cytostaining, cells were fixed in 4%p-formal-
deyde, permeablized,  and blocked  in  2% normal goat  serum 
with 0.25% Triton X-100  in PBS  for 30 min,  and probed with 
rabbit polyclonal anti-TH (1 : 1000; EMD Biosciences Inc., San 
Diego, CA, USA),  followed by FITC goat anti-rabbit  IgG. For 
western blot analysis, 10 μg of protein sample from cell lysates 
of each treatment group was loaded onto a 12% NuPAGE Bis–
Tris  gel  (Invitrogen).  Following  transfer  onto  a  PVDF mem-
brane, the membrane was blocked and then probed overnight 
with anti-TH (1 : 1000). Signal was detected with horseradish 
peroxidase-conjugated anti-rabbit IgG (1 : 10 000; Zymed Lab-
oratories)  using  chemiluminescence  system  (SuperSignal® 
West Pico Chemiluminescent  substrate; Pierce Biotechnology 
Inc.). Densitometric analysis was performed using ImageJ soft-
ware and normalized to β-actin (1 : 1000; Abcam, Cambridge, 
MA, USA). Assays for viable and dead mammalian cells (Live/
Dead Viability/Cytotoxicity;  Invitrogen) were  performed  ac-
cording to manufacturer’s protocol. The protocol was revised 
so that the concentration of each dye was 1 μmol/L to avoid 
high background. Live cells were distinguished by the uptake 
of calcein acetoxymethyl ester to acquire a green fluorescence 
[excitation/emission  (ex/em)  495/515 nm],  while  dead  cells 
acquired a red fluorescence (ex/em 495/635 nm) because of the 
uptake of ethidium homodimer-1. Cell enumerations were per-
formed using fluorescence microscopy (200× magnification) 
and a M5 microplate fluorometer (Molecular Devices, Sunny-





Protein purification, 2D DIGE, and DeCyder 
analyses










2D Quant (GE Healthcare). Samples of control and stimulated 
cell lysates (25 μg of each lysate) were labeled with 400 pmol of 
CyDye 2. A 50 μg protein sample of control cell lysate was la-




buffer to a total volume of 450 μL, then loaded onto an immo-
bilized pH gradient strip, and left for 18 h for rehydration. In 




ager with ex–em filters at 540/590 nm for CyDye 3 dyes and 
620/680 nm for CyDye 5 dyes (GE Healthcare). Analysis of Cy-
Dye 3-CyDye 5 image pairs, adjustment to CyDye 2 control im-
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ages, and detection of protein spots with relative spot volumes 
were performed using DeCyder  software  (GE Healthcare)  to 





Waltham, MA, USA). Protein identification was completed us-
ing BioWorks 3.1 software.
  
In gel tryptic digestion and protein  
identification by LC-MS/MS
Specific protein spots were excised from the gels by an au-
tomated Ettan spot picker. Following column purification (Zip-
Tip CU-18; Millipore) with 50% acetonitrile (ACN), 50 mmol/L 
NH4HCO3/50% ACN, and 10 mmol/L NH4HCO3/50% ACN, 
gel pieces were dried and incubated with trypsin (100 ng/μL) 
(Promega, Sunnyvale, CA, USA) for 12–18 h. Samples were ex-
tracted by 0.1% trifluoroacetic acid/60% ACN, pooled, and 
dried.
Dried  peptide  samples  were  reconstituted  in  0.1%  formic 
acid/HPLC-grade water, detected on a ProteomeX LCQTM 
DECA XP Plus mass  spectrometer  (ThermoElectron  Inc.),  and 
identified using BioWorks 3.1SR software. Proteins identified by 



















and stored at −80°C. Protein lysates were prepared from indi-
vidual samples through homogenization in RIPA buffer supple-
mented with protease inhibitors (Pierce Biotechnology Inc.). Pro-
tein quantification was performed using the bicinchoninic acid 
kit  (Pierce  Biotechnology  Inc.).  Protein  concentration  of  each 
sample  was  determined  using  a  calibration  curve  generated 
from purified bovine serum albumin. A total of 20 μg of each 
sample was loaded onto 4–12% Bis–Tris NuPAGE gels (Invitro-
gen) and transferred onto PVDF membranes (BioRad). Primary 
antibodies to calmodulin (1 : 1000) and 14-3-3σ (1 : 200) (Milli-
pore), biliverdin reductase (1 : 5000), thioredoxin (1 : 2000), β-ac-
tin (1 : 5000), and α-tubulin (1 : 5000) purchased from Abcam, l-
plastin (1 : 1000), α-enolase (1 : 1000), glutathione-S-transferase 
(1 : 1000), and NF-κB p65 and p50 (1 : 200) purchased from Santa 
Cruz  Biotechnology  Inc.  were  used  for  analyses.  Blots  were 
probed with  the  respective horseradish peroxidase-conjugated 
secondary  antibodies  (1 : 5000;  Invitrogen)  and detected using 
SuperSignal West Pico Chemiluminescent substrate (Pierce Bio-





All  values  are  expressed  as  mean ± SEM.  Differences 
among means were analyzed by Student’s t-test or by one-way 





Aggregated N-α-syn and microglial activa-
tion: laboratory and pathological studies
To investigate the mechanisms by which N-α-syn-me-
diated  microglial  activation  affects  dopaminergic  neu-
rodegeneration, we created a cellular model that would 
reflect the salient features of neuroinflammation as it 
could occur in PD. To this end, we first determined if 
N-α-syn was present in regions of brain where microg-
lial activation is known to be present in PD. Whole cell 
lysates consisted of several protein bands following gel 
electrophoresis  (data not  shown) and Coomassie  stain-
ing (data not shown). IP assays performed from SN tis-
sues  of  PD  patients  using  a  primary  antibody  against 







encompassing the 14–14.5 kDa of the anti-N-α-syn IP 
contained peptides with sequence homology to human α-
syn in SN samples recovered from PD brains (Figure 1a, 
highlighted sequences). Interestingly, such sequence ho-
mologies to α-syn were not identified from 14 to 14.5 kDa 
proteins in either control or AD samples. Thus, we next 
sought to develop an in vitro model to reflect conditions 
present in an affected human host, but using the murine 
analog. Here, recombinant mouse α-syn was purified, 
nitrated, and aggregated  for use as a microglial  stimu-
lant. Western blot assays showed cross-linking of N-α-
syn monomers (Souza et al. 2000) and higher molecular 
weight aggregates,  thus verifying  the nitration and ag-




tion was also assessed by AFM. Samples of N-α-syn con-
tained  low numbers  of  globular  aggregates  (2–6 nm  in 
height) prior to aggregation. However, following aggre-
gation, N-α-syn was present predominately as oligomers 
(2–6 nm in height). In addition, there were few protofi-
brils (1.5–2.5 nm in height), filaments, and fibrils (~5–
8 nm in height) present (Figure 1c). Non-nitrated α-syn 
was present in similar configurations (data not shown).
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  We next evaluated the stimulatory effects of N-α-syn on 
microglia. The dose of 100 nmol/L (14.5 ng protein/mL) 
was  selected  based  on  previous  extensive  works  per-
formed  in  our  laboratories demonstrating  that,  follow-
ing a dose-response of N-α-syn, 100 nmol/L (50% over 
control) is required to induce substantive ROS from ac-
tivated microglial cells (Zhang et al. 2005; Thomas et al. 
2007) as well as cytotoxicity. ROS production was slightly 
decreased in comparison with either 50 or 500 nmol/L of 
N-α-syn. While native α-syn is ubiquitously expressed, 
the physiological concentration of N-α-syn in disease has 
not been elucidated. However, based on concentrations 
of modified α-syn in affected PD brain tissues, 100 nmol/
L concentration is at physiologically relevant levels (Hal-
Figure 1.  α-Syn nitration, aggregation, and microglial activation. (a) Coomassie stain of anti-N-α/β-synuclein immunoprecipi-
tation from SN from control and PD brains. Arrowhead reflects the area excised from gel and submitted for LC-MS/MS analysis. 
Equal concentrations of proteins from control and experimental brain tissues served as loading controls. Peptides obtained by 
LC-MS/MS that matched human α-syn are highlighted within the full-length sequence. (b) Western blot analyses of recombinant 
mouse α-syn and derivatives. Lane 1 is a nitrotyrosine modified protein provided by the manufacturer. Lanes 1–3 were blotted 
and probed with anti-nitrotyrosine, and lanes 4–6 were probed with anti-synuclein. (c) AFM images are shown for unaggregated 
(0.4 × 0.4 mm) and aggregated N-α-syn (1.6 × 1.6 mm). Arrow indicates location of inset photomicrograph. Scale bar corre-
sponds to height of aggregates on the interface. (d) Microglial morphology after exposure of microglia to media alone (control, 
left) or 100 nmol/L N-α-syn (center), and N-α-syn stimulated microglia in co-culture with MES23.5 cells (right; scale bar: 25 μm). 
Cells were stained with calcein AM to detect viable cells. (e) Cytokine bead arrays were used for flow cytometric analysis of su-
pernatants from unstimulated microglia (control, open box) and microglia stimulated with either 100 nmol/L N-α-syn (closed tri-
angle) or 100 ng LPS (closed circle) (n = 3, p < 0.01 vs. aControl and bLPS at each corresponding time point). 
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liday et al. 2005) and is below that detectable by immu-
nohistochemistry  in neuronal  inclusions within  the SN 
of PD brains (≥ 100 ng). Phenotypic transformation into 
an  ameboid morphology  commonly  follows microglial 
activation with different pro-inflammatory stimuli (Gi-
ulian  et al.  1995; Vilhardt  2005).  Thus, we  examined  if 
changes in microglial morphology would be elicited fol-
lowing N-α-syn activation. Resting microglia were both 
round and ellipsoid shaped with retracted processes that 
were  characteristic  of  a  relatively  quiescent  phenotype 
(Figure 1d). In contrast, N-α-syn activated microglia as-
sumed a more ameboid appearance with extensive pro-
cesses, characteristic, in part, of an activated phenotype. 




gated N-α-syn could activate microglia to produce co-
pious amounts of ROS (Thomas et al. 2007). In contrast, 
unaggregated N-α-syn or minced neuronal membrane 
fractions failed to induce significant amounts of ROS 
above control levels. This suggested that the microglial 
response to N-α-syn was specific and could not be elic-
ited in response to unaggregated protein or by phagocy-
tosis under the same conditions. Therefore, we assessed 
the extent of the neuroinflammatory phenotype induced 
by N-α-syn stimulation of microglia. Quantification of 
common cytokines and chemokines that are secreted in 
response to inflammatory stimuli was performed by cy-
tometric bead array. LPS-activated microglia served as a 
positive control. Stimulation with N-α-syn enhanced the 
secretion of TNF-α, IL-6, MCP-1 (Figure 1e), and IFN-γ 
(data not shown) compared with basal  levels observed 
in unstimulated microglia.  These  results  are  consistent 
with the induction of an inflammatory microglial phe-
notype following N-α-syn stimulation. The parallels be-
tween N-α-syn and LPS-induced cellular effects support 
a commonality for innate immune responses in disease 




N-α-syn-stimulated microglia are neuro-
toxic to MES23.5 dopaminergic cells





suring  immunoreactivity  for  the  rate-limiting  enzyme 
in dopamine synthesis, TH, expressed by MES23.5 cells, 
and the Live/Dead cell assay. During stimulation with 
100 nmol/L N-α-syn, the number of TH+ cells declined 
in the stimulated cultures, resulting in a significant dim-
inution  in TH-immunoreactive cells  (8 h: 74.6% of con-
trol; 24 h: 53.4% of control, p < 0.01; 72 h: 48.5% of con-
trol,  n = 6,  p < 0.01). Western blot analysis confirmed 
this observation, as TH expression decreased in a time-
dependent manner over the course of N-α-syn stimu-




L of N-α-syn followed by MES23.5 co-culture resulted 
in  remarkable  reduction  of  viable  cells  with  concomi-
tant increase in dead MES23.5 cells; whereas, fewer dead 
cells were observed  in co-cultures with microglia stim-
ulated with α-syn (non-nitrated) after 24 h (Figure 2a). 
Percentage of MES23.5  cell  survival was  less  in  co-cul-
tures with microglia stimulated with α-syn (83%) and N-
α-syn (58%) compared with unstimulated controls (95%) 
at 72 h (Figure 2b). The more sensitive fluorometric anal-
ysis  revealed  as  early  as  24 h  after  stimulation  a  simi-
lar  pattern  of  progressive decline  in  viable  cells  in  the 
presence of α-syn and N-α-syn stimulated microglia to 
76% and 65% of controls at 24 h of stimulation, respec-
tively (Figure 2c). Moreover, N-α-syn-mediated cytotox-
icity was restricted to MES23.5 cells, as stimulation of mi-
croglia  in  the absence of MES23.5 cells neither affected 




N-α-syn in the absence of microglia (Figure 2d). Further-
more aggregation of N-α-syn was necessary for induc-
ing microglia cytotoxicity (Figure 2d). Importantly, a de-
crease in the cell survival was observed when microglia 
were stimulated with either aggregated α-syn (93%) or 
N-α-syn (86%) for 24 h, and co-cultured with MES23.5 
cells in transwell inserts, but not unaggregated protein. 
MES23.5 cultures incubated with supernatants obtained 





NF-κB gene expression and nuclear translo-
cation in PD
NF-κB pathway activation is critical for the initiation 
of inflammatory events including the production of in-
flammatory cytokines and chemokines linked to inflam-
mation and microglial activation. We hypothesized that 





neuropathological profiles shown Table 1) and controls 
(those without neurological disease) were analyzed  for 
NF-κB-related genes as well as neurotrophin expression 
(Figure 3). Increases, albeit modest, were seen in NFKB1 
expression  from samples of SN from PD patients com-
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Figure 2.  N-α-syn-stimulated microglia decrease dopaminergic cell survival. (a) Representative photomicrographs of Live/Dead 
assays of unstimulated or N-α-syn stimulated microglia co-cultured with MES23.5 cells for 24 h. Viable cells appear green and 
dead cells are red. (scale bars: 25 μm). (b and c) N-α-syn-induced microglial inhibition of cell survival. A time-course for cell sur-
vival is shown for MES23.5 cells and microglia co-cultured in the presence of media alone (Con, box), 100 nmol/L unmodified α-
synuclein (α-syn, triangle), or 100 nmol/L N-α-synuclein (N-α-syn, circle). Cell viability was quantified using the Live/Dead as-
say by (b) cell count (n = 9 fields, p < 0.01 compared with a0 h and ball treatment groups at corresponding time point), and by 
(c) fluorometric analysis (n = 9 fields, p < 0.01 compared with a0 h and ball treatment groups at corresponding time point). (d) 
Cell survival of MES23.5 cells in co-culture with microglia after 72 h of stimulation with either α-syn or N-α-syn (n = 9, p < 0.01 
compared with aall treatment groups and bα-syn stimulated microglia). (e) Influence of secretory factors from microglia stim-
ulated with either α-syn or N-α-syn for 24 h on MES23.5 cells was determined. Cell survival was assessed following incubation 
with supernatants or in transwell format for 24 h (n = 3, p < 0.01 compared with aall treatment groups and bα-syn-stimulated 
microglia). 
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pared with controls; whereas, no significant difference 
was  observed  for  RELA  expression  (data  not  shown). 
However, an eightfold  increase  in TNF expression was 
observed in the SN and BG together with a twofold in-
crease  in  expression  of  its  receptor TNFRSF1A. STAT1 
was minimally decreased in PD brains. Similarly, anal-
ysis of AD brain tissues as a control for neuroinflamma-
tory  pathology  also  revealed  a  moderate  induction  of 









creased greater than 10-fold in the BG but no significant 
changes were observed in the SN.
A recent investigation by immunofluorescence anal-
ysis of midbrain sections revealed a marked increase in 
expression of NF-κB p65 in the SN of PD patients com-




tissues, and lysates analyzed for NF-κB protein subunits 
p50 and p65. Increased expression of NF-κB subunits in 




N-α-syn-activated microglia and the PD 
transcriptome are linked through NF-κB
The increased expression of NF-κB transcription iden-
tified in the SN of PD brains and the microglial response to 
N-α-syn stimulation that were consistent with inflamma-
tory responses suggested that one major signaling path-
way induced by N-α-syn involves NF-κB activation. Use 
of a general microarray confirmed that NF-κB expression 
was increased by stimulation with N-α-syn (Figure 5a). 
Using NF-κB-focused microarrays (Figure 5b, Table 2), 
we showed increased expression of genes encoding pro-
inflammatory cytokines, including Tnf, Ccl2, Il6, and Il1β. 
Also induced were those genes encoding the NF-κB tran-
scription factor subunits, Nfkb1, Nfkb2, and Rela. In addi-




NF-κB-related genes peaked. The majority of genes in-
duced at 1 h remained elevated, with the addition of the 
apoptosis-regulatory genes Card10 and Casp8. The NF-κB 
inhibitor, Nfkbia, was also induced (data not shown) but 
may  become  apparent  only  after  removal  or  clearance 
of the stimulus, as Ikbkb expression was also induced at 
this time. Removal of N-α-syn from microglial cells af-
ter 4 h of stimulation reduced most NF-κB genes to pre-
stimulatory levels. At 8 and 16 h following removal of N-
α-syn from culture, several apoptosis-regulatory genes 
(Card10, Card11, and Cflar) were induced as well as genes 
for receptors of cell activation and NF-κB stimulation in-
cluding  Tnfrsf1a  and  Cd40.  These  results  were  similar 
but  lesser  in  magnitude  than  stimulation  of  microglia 
Figure 3.  Cellular activation and oxidative stress pathways in PD brain tissues. Tissue samples from the SN and BG of control 
(filled bars) and PD patients (open bars) (Table 1) were evaluated by qRT-PCR for expression of NF-κB pathway associated genes. 
The relative expression of a gene was normalized to GAPDH in the same sample and values are represented as mean ± SEM (a 
p < 0.05, b p < 0.01, and c p < 0.001 compared with samples from control patients, n = 8–10 patients per group). 




for these cytokines during stimulation by N-α-syn (10-, 
3097-, and 16-fold increases, respectively) over pre-stim-
ulatory levels (Figure 5c). Verification of gene expres-
sion during stimulation of other, less abundant, NF-κB-
related genes were achieved, including Tnfrsf1a (6.2-fold 
increase), Stat1 (2.3-fold increase), and Rela (3.6-fold in-
crease). N-α-syn stimulation also increased expression of 
Nos2 (inducible nitric oxide synthase) and Ifng (data not 




N-α-syn-activated microglial proteome 
shows a reactive inflammatory phenotype
Analysis of the N-α-syn microglial transcriptome 
showed differential gene regulation and induction of the 
NF-κB pathway, indicative of an inflammatory microglial 
phenotype. Activation of this pathway influences down-
stream expression of proteins involved in processes in-
cluding inflammation, immune regulation, survival, and 
proliferation.  Protein  expression  obtained  from  cell  ly-
sates were analyzed following 2, 4, and 8 h of stimula-
tion with 100 nmol/L N-α-syn to assess the translation of 
differences in gene induction to intracellular protein ex-
pression. Two-dimensional DIGE was used to compare 
protein expression profiles of unstimulated microglia 
(control) and N-α-syn-stimulated microglia (Figure 6). A 
complete listing of all proteins identified by LC-MS/MS 
is contained within Table 3.
Stimulation with N-α-syn resulted in differential ex-
pression of several proteins that are likely a consequence 






After 4 h of N-α-syn-stimulation, proteins decreased 
included several cytoskeletal proteins including β-actin, 
Figure 4.  NF-κB translocation in PD. Expres-
sion of NF-κB subunits p50/NFKB1 and p65/RELA 
proteins were evaluated by western blot analysis 
from whole tissue lysates (top), cytosolic fractions 
(middle), and nuclear fractions (bottom) of SN 
from control and PD patients (Table 1). Expres-
sion of phosphorylated RELA/p65 [NF-κB pS536] 
within the nuclear fraction was also assessed. 
The mean densitometric values were determined 
with ImageJ software and normalized to GAPDH 
expression in the same sample (bottom). Values 
are represented as the mean density ± SEM for 
four patients/group and p-values of Student’s t-
test for pair-wise comparisons of densities from 
control (open bars) and PD (filled bars) patients 
are * p < 0.05 and ** p < 0.005. Blots are repre-
sentative of two independent experiments (n = 4 
patients per group). 
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cofilin-1, profilin-1, tropomysin-3, and vimentin. The pu-
tative functions of other proteins decreased in N-α-syn-
stimulated microglial lysates were found to be involved 
in cell adhesion and actin microfilament attachment to 
the plasma membrane (vinculin, coronin-1A, and adeny-
lyl cyclase-associated protein 1), glycolysis and growth 
control (α-enolase), and migration (galectin 3 and mac-
rophage migration inhibitory factor) (Walther et al. 2000; 
Figure 5.  Microarray analysis of N-α-syn-stimulated microglia. RNA was isolated from microglial cells stimulated with 100 nmol/
L N-α-syn or 100 ng/mL LPS from which cDNA was made and amplified. (a) General pathway-focused microarray revealed in-
volvement of NF-κB signaling pathways. (b) Focused arrays were utilized for regulation of NF-κB associated genes for microglia 
that were unstimulated (0 h Control) or stimulated with 100 nmol/L N-α-syn or 100 ng/mL LPS for 1 h and 4 h, respectively. Red 
and green boxes indicate genes that were induced by stimulation at 1 and 4 h, respectively. Identified genes and their expression 
levels are shown in Table 1. (c) qPCR of mRNA from samples confirmed representative inductions for genes (rank and file posi-
tion in microarry) Ccl2 (F2), Il1β (H5), Tnfrsf1a (D13), Stat1 (11E), Rela (10F), Tnf (Α13), and Nos2. Gene expression for the 
neurotrophins Bdnf and Gdnf were also assessed by qPCR from the same mRNA/cDNA samples [n = 3, p < 0.01 compared with 
a0 h control (C) and bLPS at corresponding time point]. 
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Table 2.  N-α-syn- and LPS-stimulated microglial transcriptomea 
                                                                                        N-α-syn (h)                                            LPS (h)
Gene                  Common name                NCBIb             4              8              16                 4              8             16
Transcription factors
  Crebbp Crebbp 12914 2.45   2.6  
  Fos c-Fos 14281 > 20     
  Jun c-Jun 16476 2.28     
  Nfκb1 NFκB p50 18033 2.08   7.6  
  Rel Rel 19696 6.5   15.4 4.3 
  Rela NFκB p65 19697 4.59     
  Smad3 Smad3 17127  −2.5    
Signal transduction
  Htr2b Serotonin receptor 15559 3.56 −2.38    
  Ikbkb Ikbkb 16150 5.19   2.7  
  Ikbke Ikbke 56489 3.09     
  Mapk3 Mapk3 26417 2.67     
  Map3k14 Map3k14 53859  −2.34 −2.4 −2  
  Plk2 Plk2 20620  2.39 2.04 3.1 4.1 2.5
  Raf1 Raf-1 110157 5.63     
  Stat1 Stat1 20846 5.56 3.5  5.1 5.2 3.2
  Tbk1 Tbk1 56480 4.24     4.6
  Tgfbr2 TGF-beta receptor 2 21813  −3.91  −2.8 −2.6 
  Tlr2 Toll-like receptor 2 24088 7.38  2.43   
  Tlr3 Toll-like receptor 3 142980  −2.2    
  Tlr8 Toll-like receptor 8 170744 2.38     
  Tnfrsf1a TNFR1 21937  2.03 4.06 5.7 8.6 2.7
Inflammation
  Tnf  TNF-alpha 21926 2.25     
  Ccl2  Chemokine ligand 2  20296 36.43 3.83 2.68 15.1 14.7 14.5 
    (MCP-1)
  Il10  Interleukin 10 16153 2.31   5.8 4 3.1
  Il1b  Interleukin 1-beta 16176 > 20 3.02 2.27 10.7 10.1 9.9
  Il6  Interleukin 6 16193 13.09  2.57 78.1 25.4 2.3
  Tnfrsf5  CD40 21939 9.91 25.6 7.23 145.1 135.5 45.7
  Tnfrsf7  Tnfrsf7 21940  −3.14    
  Traf6  Traf6 22034  −2.71    
Apoptosis
  Card10  Card10 105844 5.62 8.34 7.9 10.7 10.6 11.1
  Card11  Card11 108723   2.63   
  Card4  NOD1 107607 7.44   8.6 5.5 5.4
  Casp1  Caspase 1 12362 4.3     
  Casp8  Caspase 8 12370 2.49     
  Cflar  Clarp 12633 19.65 2.22 2.08 8.6 7 6.7
  Ripk1  Receptor (TNFRSF)- 19766  −2.6  2.1 
    interacting serine- 
    threonine kinase 1   
  Malt1  Malt1 240354 6.1   6.2  
  Ripk2  Cardiak 192656 6.16   9.5 7.3 
  Tnfaip3  A20 21929   6.55 8.9 3.2 
  Tnfsf10  TRAIL 22035  10.06    
  Tradd  Tradd 71609   2.43 2.2  
  Traf3  CD40BP 22031 2.03     
Other
  Csf2  GM-CSF 12981 3.76     
  Dusp1  Dusp1 19252 3.15   6 6.2 5.3
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Chandrasekar et al. 2005). Annexin A3 is an inhibitor of 
phospholipase  A2  and  a  promoter  of  apoptosis  of  in-
flammatory cells (Parente and Solito 2004), and was also 
down-regulated. The antioxidant glutaredoxin-1 was also 




ulin,  calreticulum,  and nucleophosmin  1)  (Parente  and 
Solito 2004; Vuadens et al. 2004; Meini et al. 2006).
By  8 h,  73  proteins  were  differentially  expressed. 
Thirty-three proteins were decreased including all cyto-
skeletal proteins down-regulated at 4 h, vimentin and β-
actin.  Up-regulated  proteins  included  the  antioxidants 
superoxide  dismutase,  thioredoxin,  and  cytochrome  c 
reductase. Oxidative stress can also lead to dysfunction 
of the proteasome and is implicated in PD pathogenesis 
(Gu et al. 2005). Indeed, as a result of N-α-syn stimulation 
the proteasome 26S subunit was decreased in these cell 





Neuroinflammatory Parkinson’s disease 
phenotype
Analysis of the proteome of N-α-syn-stimulated mi-
croglia revealed the induction of NF-κB-related signal-
ing pathways and initiation of several proteins involved 
in the cellular response to inflammation and oxidative 
stress. To investigate whether differential expression of 
proteins identified in our proteomic analyses of in vitro 
stimulated microglia was reflected in PD, protein expres-
sion of  lysates prepared from the SN and BG (data not 
shown) of control and PD brains were assessed by west-
ern  blot  assays  (Figure 7).  Proteins  increased  in  abun-
dance within the secretome as a result of N-α-syn stimu-
lation (A. D. Reynolds, I. Kadiu, S. G. Garg, J. G. Glanzer, 
T. Nordgen, R. Banerjee, P. Ciborowski, and H. E. Gen-
delman) were  cross-validated  in PD patients  including 
calmodulin  and  the  redox-associated  secreted  proteins 
biliverdin reductase and thioredoxin; whereas, secretion 
of the regulatory proteins glatectin-3 and 14-3-3σ, struc-
tural protein actin, and the redox protein glutathione-S-
transferase were decreased following N-α-syn stimula-





coincided with our analysis of the N-α-syn-stimulated 
microglia  secretome.  In  contrast  to  our  in vitro  results, 




the SN, expression in the BG was significantly decreased 
in PD (data not shown). Proteins that were identified in 
the proteome of N-α-syn-stimulated microglia were, in 
part, also cross-validated in SN of PD and control brains. 
Akin to our laboratory model, expression of calmodulin 
was increased whereas expression of α-enolase (data not 









osis  is  present. However,  overall  these  results  support 
that the molecular and biochemical analyses of N-α-syn 




Recent investigations (Biasini et al. 2004; Zhang et al. 
2005; Zhou et al. 2005; Thomas et al. 2007) demonstrated 
that aggregated N-α-syn induces a neurotoxic inflam-
matory microglial phenotype that accelerates the demise 
of dopaminergic neurons, and as such, may contribute, 
Table 2.  (continued)
                                                                                               N-α-syn (h)                                     LPS (h)
Gene                  Common name                NCBIb               4              8            16                4              8             16
  Hmgb1  Hmgb1 15289 2.96   2.2  
  Icam1  Icam1 15894 12.79 4.97 3.46 5.2 4.8 3.8
  C3  Complement component 3 12266 2.02     
  Irak1  Interleukin-1  16179 2.19 
    receptor-associated  
    kinase 1      
 Lta  Lymphotoxin A 16992 3.09   22.8  
a Values represent fold-change versus unstimulated controls; b NCBI Entrez GeneID.
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Table 3.  N-α-syn-stimulated microglial proteome 
                                                                                                          Accession           Time     Number of      Volume 
Protein name                                                  Mw (Da)b         PIc            numberd            (h)e       peptidesf         ratiog
Proteins increased in N-α-syn-stimulated microglia cell lysates when compared with controls a 
Regulatory
  10 kDa Heat-shock protein, mitochondrial  10 825 8.18 Q64433  8 6 3.45
  S100 calcium-binding protein A13  11 151 5.89 P97352  8 2 5.57
  Apoptosis-associated speck-like protein  
      containing a CARD 21 459 5.26 O88597  2 6 1.58
  Beclin-1 51 534 4.89 O88597  2 2 1.48
  Calmodulin 16 706 4.09 P62156  8 3 7.51
  Calreticulin 47 995 4.33 P14211  8 7 1.67
  Cystatin B 11 039 6.82 Q62426  8 2 3.06
  Dynein light chain 2A 10 852 6.86 P62627  8 3 3.73
  Ef3-CaM  16 578 4.04 P99027  2 8 2.26
  Eukaryotic initiation factor 5A isoform I  
      variant D 16 821 5.08 Q7L7L3  4 2 1.51
  Fatty acid-binding protein  14 996 6.18 Q05816  2 3 3.17
  Heat-shock 70 kDa protein 1A  70 052 5.48 Q9EPB4  4 2 1.43
  Heat-shock 70 kDa protein 1B  70 167 5.53 P17879  4 2 1.79
  Heat-shock 70 kDa protein 1L  70 637 5.91 P16627  8 2 1.79
  Histone H2B F 13 805 10.32 P10853  2 2 4.07
  Kinesin light chain 4 68 613 5.76 Q5JQI4  8 2 1.85
  Mitogen-activated protein-binding  
      protein-interacting protein  13 472 5.3 Q9JHS3  8 2 4.75
  Nucleophosmin 1 32 558 4.62 Q5U438  8 9 1.68
  SH3 domain-binding glutamic  
      acid-rich-like protein 3 10 470 5.02 Q91VW3  8 4 3.12
  SWIPROSIN 1/EF hand domain  
      containing protein 2 (Efhd2) 26 800 5.07 Q8C845  8 2 2.06
  Ubiquitin  8560 6.56 P62990  8 2 4.88
Structural/cytoskeletal
  Capg protein 39 240 6.73 P24452  8 11 1.71
  Capping protein  38 691 6.73 Q3TNN6  4 2 1.24
  Cofilin-1  18 401 8.26 P45592  2 5 3.28
  Destrin  18 378 8.2 Q9R0P3  8 6 3.04
  Myosin heavy  223 083 5.64 P02564  4 2 1.27
  Talin  110 842 5.94 Q3TBC3  2, 4 4 1.58
  Tubulin alpha-1 chain 50 152 4.94 P68361  8 7 1.92
Redox
  Isovaleryl-CoA dehydrogenase 46 325 8.53 Q9JHI5  8 7 1.71
  Cytochrome c oxidase, subunit Vb  13 838 8.34 Q9D881  8 3 3.98
  Peroxiredoxin-1 22 176 8.26 P35700  2 20 1.42
  Peroxiredoxin-4 31 053 6.67 O08807  2 2 1.42
  Peroxiredoxin-5 21 897 9.1 P99029  2 2 1.48
  Superoxide dismutase 24 603 8.8 P09671  2 2 1.42
Enzymes
  Cathepsin C  52 347 6.41 Q3TIF1  4 2 1.29
  Cathepsin Z  34 175 6.13 Q9ES94  8 4 1.69
  Ferritin heavy chain 20 935 5.53 P09528  2 4 1.44
  Hexosaminidase B  61 115 8.28 P20060  2 8 2.67
  Peptidyl-prolyl cis-trans isomerase A  17 960 7.74 P17742  8 14 4.77
  Ubiquitin-conjugating enzyme E2N  17 127 6.13 P61089  8 5 3.26
  Ubiquitin-conjugating E2 Q2 42 192 4.9 Q7YQJ9  4 5 1.3
  Vacuolar ATP synthase subunit G1 13 362 5.52 Q9D1K2  8 3 4.23
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Table 3.  (continued) 
                                                                                                          Accession           Time     Number of      Volume 
Protein name                                                  Mw (Da)b         PIc            numberd            (h)e       peptidesf         ratiog
Other
  Annexin A5 35 752 4.83 P48036  8 4 1.7
  39S ribosomal protein L12  21 695 9.34 Q9DB15  4 3 1.26
  Apolipoprotein A  35 853 5.56 Q6GTX3  8 5 1.73
  Fatty acid-binding protein (E-FABP) 15 006 6.18 Q05816  8 2 3.52
  Fibulin 2  126 414 4.55 Q3TGL4  8 2 5.57
  Heterogenous nuclear ribonucleoprotein K 50 976 5.39 P61979  8 8 1.69
  Prosaposin 61 086 5.11 Q3TID4  8 3 10.1
Proteins decreased in N-α-syn-stimulated microglial cell lysates a 
Regulatory           
  14-3-3 Protein epsilon  29 155 4.63 P62259  8 8 −3.33
  26S protease regulatory subunit 7  48 517 5.72 P46472  8 2 −2.4
  Acyl-CoA binding protein 9863 8.78 P31786  4 8 −3
  Adenylyl cyclase-associated protein 1 51 444 7.3 P40124  8 9 −1.9
  Centromere protein F  367 594 5.03 P49454  2 3 −1.68
  Chloride intracellular channel protein 1  26 865 5.09 Q9Z1Q5  8 3 −3.28
  Coronin1B  53 912 5.54 Q9WUM3  4 3 −1.26
  Eukaryotic translation initiation factor 3  35 586 5.69 Q3THA0  8 2 −3.32
  Galectin 3 27 384 8.5 P16110  4 13 −2.34
  Heterogenous nuclear  
      ribonucleoproteins A2/B1  35 992 8.67 O88569  2 5 −1.61
  Macrophage Migration Inhibitory factor  12 373 7.28 P34883  8 3 −2.03
  Nuclear migration protein nudC  38 334 5.17 O35685  8 7 −4.13
  Programmed cell death 6-interacting protein  96 010 6.15 Q9WU78  4 8 −1.25
  SH3 domine-binding Glutamic  
      acid-rich-like protein 10 477 5.02 Q91VW3  8 12 −1.81
  Synaptotagmin-like protein 2  106 806 6.14 Q99N50  2 2 −1.46
Structural/cytoskeletal           
  Beta-actin 41 737 5.78 P60710  4 26 −3.69
  Coronin-1A  50 989 6.05 O89053  8 10 −2.4
  Desmin  53 334 5.21 P31001  8 13 −3.25
  Gamma actin-like protein  43 572 5.11 Q9QZ83  8 27 −4.03
  Gelsolin  80 712 5.47 Q3U9Q8  8 7 −3.3
  L Plastin  70 018 5.2 Q61233  8 15 −2.58
  MFLJ00343 protein  205 326 5.6 Q6KAM8  8 17 −2.12
  Profilin-1  14 816 8.5 P62962  8 7 −1.35
  Tropomodulin  40 441 5.02 Q3KP84  8 2 −4.13
  Tropomysin-3  33 149 4.73 P21107  4 10 −1.25
  Tubulin alpha 4  49 761 4.95 Q3TY31  8 7 −3.23
  Tubulin alpha 6  49 907 4.96 QTIZ0  8 9 −3.25
  Vimentin  53 689 5.03 Q3TFD9  8 88 −3.38
Redox           
  Glutaredoxin 1 11 732 8.69 Q91V76  4 2 −1.7
  Thioredoxin domain containing 5  46 386 5.51 Q3TEE8  8 38 −4.24
Enzyme      
  α-Enolase 47 010 6.36 P17182  8 8 −2.4
  2’-5’ olygoadenylate synthetase 1F  42 270 7.09 Q8K465  2 7 −1.68
  3-ketoacyl-CoA thiolase A  43 935 8.74 Q921H8  8 3 −2.66
  Aconitase  98 152 5.98 Q42560  2 3 −1.59
  ATP synthase  59 751 9.16 Q53XX6  2 2 −1.55
  ATP synthase e chain 8099 9.34 Q06185  4 5 −1.52
  Carbonyl reductase  30 394 6.15 Q8K354  4 3 −1.27
  Cathepsin B  37 256 5.57 P10605  8 15 −3.34
  Cathepsin D  44 925 6.71 P18242  8 34 −3.68
  Cathepsin S 38 707 6.51 Q8BSZ5  4 3 −1.29
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in  part,  to  PD  progression. However,  the mechanisms 
underlying N-α-syn-mediated microglial neurotoxic-
ity remain obscure. To  investigate  the means by which 
N-α-syn-mediated microglial activation affects dopami-
nergic neurodegeneration,  the molecular and biochem-
ical signatures of N-α-syn-stimulated microglia were 
investigated. This report now demonstrates that microg-
lial stimulation with aggregated, nitrated α-syn leads 




atal degeneration, reflective of PD pathobiology. A key 
component of this study was the integration of physio-
logic, genomic, and proteomic  techniques  to develop a 
fingerprint of microglial cell activation following its in-
teractions with N-α-syn. This microglia phenotype was 
characterized by morphological  changes,  as well  as  al-





a microglial “fingerprint” that may be reminiscent of in-
flammatory processes in PD. The inflammatory microg-
lial phenotype now shown follows its interaction with N-




2005);  all  necessary  for  host  defense. However,  during 
neurodegenerative  diseases,  their  phenotype  is  altered 
by uncontrolled activation. Substantial evidence  for re-
active microglia  in and around dead or dying dopami-
nergic  neurons  in  the  SN  of  PD patients  suggests  that 
microglial activation and concomitant secretion of neu-
rotoxic  factors play  a  role  in  the nigrostriatal  degener-
ation  that  occurs  in  PD.  Stimulation  by  environmental 
cues that include aggregated proteins and inflammatory 
factors often results in the robust secretion of toxic fac-
tors  that accelerate neuronal  injury and death (McGeer 
and McGeer  1998;  Liu  and Hong  2003).  Cytokines  re-
leased  from  activated microglia  bind  their  cognate  re-
ceptor on dopaminergic neurons to activate signal trans-
Table 3.  (continued) 
                                                                                                          Accession           Time     Number of      Volume 
Protein name                                                  Mw (Da)b         PIc            numberd            (h)e       peptidesf         ratiog
  F1-ATPase alpha subunit  44 144 7.07 O78824  2 9 −1.55
  Fructose-bisphosphate aldolase A  39 225 8.4 P05064  8 33 −2.66
  Glutamate oxaloacetate transaminase 2  47 183 9.05 Q3TIP6  4 3 −1.23
  Phosphomannomutase 2  27 625 6.01 Q9D1M5  4 3 −1.3
  Succinyl-CoA ligase beta chain, mitochondrial  50 082 6.57 Q9Z219  8 3 −4.12
  Transitional endoplasmic reticulum ATPase  53 524 4.14 Q01853  8 19 −3.31
Other      
  Annexin A1 38 603 7.15 P10107  8 8 −1.9
  Annexin A3 36 240 5.33 O35639  8 5 −1.93
  28S ribosomal protein S12, mitochondrial  15 437 10.72 O35680  2 2 −1.63
  Arcn1 protein  47 964 5.61 Q8R1S6  8 7 −1.93
  Beta-galactoside-binding lectin  15 914 9.01 Q61357  4 7 −1.84
  Centrosomal protein of 27 kDa  26 839 6.06 Q9CQS9  2 3 −1.68
  Clathrin light chain B  25 171 4.56 Q6IRU5  2 3 −1.68
  Density regulated protein  22 152 5.21 Q9CQJ6  8 2 −3.48
  Fatty acid binding protein 14 996 6.18 Q05816  4 4 −1.27
  Glycoprotein (transmembrane) nmb  63 577 7.88 Q3TAV1  8 2 −3.13
  Gsn protein  80 763 5.52 Q6PAC1  8 13 −1.66
  Histone H2A type 1  14 004 11.05 P22752  8 2 −5.46
  Protective protein for beta-galactosidase  53 795 5.56 Q9D2D1  4 3 −3.47
  Vinculin 116 586 5.77 Q64727  8 9 −1.82
a The CID spectra were compared against those of the EMBL non-redundant protein database by using sequest (ThermoElectron, 
San Jose, CA, USA). After filtering the results based on cross-correlation Xcorr (cutoffs of 2.0 for [M + H]1+, 2.5 for [M + 2H]2+, 
and 3.0 for [M + 3H]3+), peptides with scores greater than 3000 and meeting delta cross-correlation scores (ΔCn) > 0.3, and 
fragment ion numbers > 60% were deemed valid by these sequest criteria thresholds, which have been determined to afford 
greater than 95% confidence level in peptide identification; b Theoretical molecular mass; c Isoelectric point; d Accession num-
bers for UniProt (accessible at http://www.ipr.uniprot.org/search/textSearch.shtml);e Hours following stimulation with N-α-syn; 
f Number of peptides identified for each protein selected based on the above mentioned criteria; g Volume ratio indicates fold-
change versus control.
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duction pathways resulting in apoptosis or necrosis. The 
persistent activation of microglia in response to dopami-
nergic neuron  injury has been  investigated  extensively 
using the neurotoxin, MPTP. Work from several labora-
tories has documented that microglia activation accounts 
for  ~90%  of MPTP-induced  neuronal  death  (Wu  et al. 
2003; McGeer  and McGeer  2004).  Furthermore,  studies 
show MPTP neurotoxicity may be attenuated in mice un-
able to mount pro-inflammatory responses (Feng et al. 
2002; Sriram  et al.  2002; Teismann  et al.  2003; Wu  et al. 
2003), by treatment with anti-inflammatory drugs (Liu et 
al. 2006) and antioxidants (Zbarsky et al. 2005), blockage 
of the NF-κB pathway (Ghosh et al. 2007), or by induc-
tion of a  regulatory T-cell  response  (Benner  et al.  2004; 
Laurie et al. 2007; Reynolds et al. 2007); all converging on 
attenuating microglial activation.  In contrast, exacerba-
tion of microglial activation by infiltrating effector lym-
phocytes to modified self-peptides may worsen MPTP-
induced neurodegeneration (E. J. Benner, R. Banerjee, A. 
D. Reynolds, S. Sherman, V. M. Pisarev, V. Tsiperson, C. 
Figure 6.  2DE and LC-MS/MS analysis of the N-α-syn-stimulated microglia proteome. Fluorescence 2D DIGE analysis of N-α-
syn-activated microglial cell lysates. Fluorescence 2D DIGE (2DE) analysis of activated microglial cell lysates at 2, 4, and 8 h af-
ter N-α-syn stimulation. Proteins from cell lysates of unstimulated microglia labeled with Cy3 appear green on the 2 dimensional 
gels, while proteins of N-α-syn stimulated microglia labeled with Cy5 appear red, and proteins common to both appear yellow. 
Three-dimensional DeCyder interpretation for six representative proteins per time-point are shown. The numbers correspond to 
the protein spot labeled on gels. Analysis of spot distribution to locate and define protein spots (right panel). Protein spots from 
samples of stimulated cell lysates were identified as decreased (blue), increased (red), or common (yellow) versus non-stimu-
lated cell lysates. Spots picked for sequencing analysis with LC-MS/MS are shown in purple. Abbreviations: HSP70, heat-shock 
protein 70; Cyt c oxidase, cytochrome c oxidase; SOD, superoxide dismutase. A complete listing of all proteins identified through 
2DE is contained within Table 3. 






and nitration of proteins, DNA modifications, and lipid 
peroxidation. Oxidation and nitration of α-syn leads to 
formation of aggregates and the stabilization of assem-
bled filaments found to be a major component of LBs, 
the  hallmark  lesions  of  PD.  The  results  of  the  present 
study, as well as research performed by others (Biasini 
et al. 2004; Zhang et al. 2005; Zhou et al. 2005; Thomas et 
al. 2007) support the hypothesis that microglia activated 
by N-α-syn is a component of an inflammatory cascade 
that perpetuates nigrostriatal degeneration in PD. First, 
nitrated α-syn was identified in extracts from the SN of 
PD patients in copious concentrations relative to control 
and AD brains. Second, α-syn aggregates released from 
LB  during  dopaminergic  neuronal  death  can  interact 
with adjacent microglial cells found in abundance within 
the SNpc of PD patients (Spillantini et al. 1997; McGeer 
and McGeer 1998; Croisier et al. 2005). Alternatively, α-
syn may also be released or secreted from the cytosol of 
dopaminergic  cells  into  the  extracellular  environment 
where  it  is  more  prone  to  aggregation  and  oxidative 
damage (Kakimura et al. 2001; Lee et al. 2005; Sung et al. 
2005). Third, microglial activation is associated with de-
generating dopaminergic neurons and deposition of α-
syn in the SN of PD patients (Croisier et al. 2005). Fourth, 
native and nitrated α-syn activate microglia with release 
of ROS and  induce neurotoxicity  as  shown herein  and 
by others (Zhang et al. 2005; Thomas et al. 2007). Fifth, re-
cent evidence supports that N-α-syn drains to the cervi-
cal lymph nodes, availing it for processing and presenta-
tion by antigen-presenting cells to the adaptive immune 
system, which  in  turn  can  circumvent  or  break  immu-
Figure 7.  N-α-syn-stimulated microglial proteins in PD brain tissue. Immunoblot identification of proteins in the SN and BG of 
PD brains that were previously observed in N-α-syn-stimulated microglia. This includes 14-3-3σ, calmodulin, galectin-3, l-plas-
tin, actin, tubulin, glutathione-S-transferase, thioredoxin, and biliverdin reductase. The proteins are divided into regulatory, cyto-
skeleton, or redox functions. The mean densitometric values were determined with imageJ software and normalized to GAPDH ex-
pression in the same sample (bottom). Values are represented as the mean density ± SEM for four patients/group and p-values 
of Student’s t-test of pair-wise comparisons of densities from Control (open bars) and PD (closed bars) patients are * p < 0.05 
(** p < 0.05 and congruent results with the N-α-syn-microglial proteomic and western blot assays). 






H. E. Gendelman, unpublished data). Moreover, α-syn 
and its modified forms are present in extracellular bio-
logical fluids including human plasma (El-Agnaf et al. 
2003) and are proposed as biomarkers for disease (Fjor-
back et al. 2007). Evidence of systemic complications as-
sociated  with  PD  including  abnormal  gastrointestinal 




et al. 2005; Zhou et al. 2005; McLaughlin et al. 2006). By us-
ing proteomic analyses for examination of the activated 
microglial  proteome  it  provides  human  disease  corre-
lates  while  permitting  an  integrated  cross-disciplinary 
proteomic  approach  towards  elucidating a PD microg-
lial “fingerprint.” The work provides evidence that such 
a profile is inflammatory and may be linked to neurotox-
icity. However, one must exert caution in over interpret-
ing these experimental results. Nonetheless, whether or 
not these findings are directly linked to the pathogene-
sis of PD will certainly require further study. Although 




Parallels are demonstrated herein between N-α-syn 
and  LPS  for microglial  activation  and  support  a  com-
monality  for  innate  immune  responses  in  disease.  The 




to LPS can lead to neuroinflammation associated with 
increased expression of pro-inflammatory cytokines, 
NADPH oxidase-mediated release of superoxide (Gao et 
al. 2002), and activation of the NF-κB pathway (Qin et al. 
2007) resulting in neurodegeneration. Microglial activa-
tion by LPS and N-α-syn were associated with induction 
of the ΝF-κB and mitogen activation pathways, charac-
teristic of an inflammatory phenotype. However, key dif-
ferences in the inflammatory responses induced by LPS 
or N-α-syn were identified, including genes involved in 
signal transduction and apoptosis, as well as  induction 
of an inflammatory response that was greater in magni-
tude after  stimulation with LPS compared with  that of 
N-α-syn. It is possible that the differences in transcrip-
tion may be dose or pathway dependent as the stimula-
tory capacity and pathways activated by the two stimuli 
may differ significantly. Having demonstrated that N-α-
syn stimulation induces microglial activation, this model 
may be used to study PD and reflect the unique molecu-
lar changes that occur during disease progression.
Our finding suggests that modifications to α-syn may 
be  a  common denominator  for microglial  activation  in 
sporadic and familial PD. These observations also iden-
tify  prospective  pathways  that  are  associated with  PD 
and as such uncover potential targets for therapeutic in-
tervention. For instance, identification of NF-κB activa-
tion by microglia  in response  to divergent stimuli sug-
gests that activation of NF-κB and its related signaling 
pathways may be a key component in the inflammatory 
response  leading  to neuronal death. The microglial  re-
sponse to N-α-syn was linked to neurotoxicity. Nonethe-
less, we also showed proteomic fingerprints that were 





found between the acute  in vitro model of N-α-syn mi-
croglial  stimulation  and  what  is  present  in  PD  brains 
support that ongoing inflammatory responses present 
in disease may affect CNS protective responses. The ob-
servations of sustained NF-κB activation and differential 
expression of regulatory, structural, and redox proteins 
at end-stage disease support, in part, a persistent inflam-
matory process that could affect dopaminergic loss.
In summary, a mechanistic role for aggregated N-α-
syn  in  stimulating  a  neurotoxic  microglial  phenotype 
was observed. In this ‘potential’ scheme, a pathogenic 
paracrine  loop  of  immune  activation  occurs  consisting 
of dopaminergic neuronal injury or death, release of ag-
gregated N-α-syn from the cytosol or LB either through 
exocytosis  or  neuronal  degeneration  into  the  extracel-
lular milieu, microglial  activation with  release  of  toxic 
factors which, may ultimately  lead  to  further neuronal 
injury and sustained α-syn release. Regardless of con-
current pathogenic events in PD, which initiate dopami-
nergic degeneration or the mechanisms associated with 
activation by N-α-syn, the resultant activation of res-




tions  also  provide  a  novel  approach  towards  elucidat-
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